Assessing neuro-oncology clinical trial impact and value: Testing a novel multi-criteria decision analysis app
Open Access
- 25 October 2023
- journal article
- research article
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 118, 70-78
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment OptionsJournal of Clinical Oncology, 2015
- A Practical Guide to Value of Information AnalysisPharmacoEconomics, 2014
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- Multicriteria decision analysis in oncologyHealth Expectations, 2014
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- Biomedical research: increasing value, reducing wasteThe Lancet, 2014
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical TrialJournal of Clinical Oncology, 2013
- Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade GliomaJournal of Clinical Oncology, 2010
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005